mk 0663 has been researched along with chloroquine in 3 studies
Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
---|---|---|---|---|---|
549 | 173 | 265 | 16,405 | 763 | 4,029 |
Protein | Taxonomy | mk 0663 (IC50) | chloroquine (IC50) |
---|---|---|---|
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
Procathepsin L | Homo sapiens (human) | 5.47 | |
Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
Beta-secretase 1 | Homo sapiens (human) | 7 | |
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
3 other study(ies) available for mk 0663 and chloroquine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |